Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14801560 | 1.00 | ABCB1 (0.46) | ABCB1TAS1R3TAS1R1NPC1RAB9A | |
| SCHEMBL14801637 | 1.00 | ABCB1 (0.46) | ABCB1TAS1R3TAS1R1NPC1RAB9A | |
| SCHEMBL17025742 | 0.93 | ABCB1 (0.39) | ABCB1TAS1R3TAS1R1 | |
| SCHEMBL17025792 | 0.92 | ABCB1 (0.47) | ABCB1NPC1RAB9A | |
| SCHEMBL22363210 | 0.90 | ABCB1 (0.54) | ABCB1TAS1R3TAS1R1NPC1RAB9A | |
| SCHEMBL19946425 | 0.90 | ABCB1 (0.54) | ABCB1TAS1R3TAS1R1NPC1RAB9A | |
| SCHEMBL17025766 | 0.90 | ABCB1 (0.54) | ABCB1TAS1R3TAS1R1NPC1RAB9A | |
| SCHEMBL19946450 | 0.90 | ABCB1 (0.46) | ABCB1TAS1R3TAS1R1NPC1RAB9A | |
| SCHEMBL22363209 | 0.90 | ABCB1 (0.46) | ABCB1TAS1R3TAS1R1NPC1RAB9A | |
| SCHEMBL17025797 | 0.85 | ABCB1 (0.52) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150240244-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2015-08-27 | — | — | US | claimed |
| CN-101883845-B | Engineered dendritic cells and uses for the treatment of cancer | INTREXON CORP | 2015-06-10 | — | — | CN | claimed |
| US-12275772-B2 | ROR-1 specific chimeric antigen receptors and uses thereof | PRECIGEN, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240263183-A1 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | PRECIGEN, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4382913-A2 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | Precigen, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-11946054-B2 | Modulating expression of polypeptides via new gene switch expression systems | PRECIGEN, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11555197-B2 | Control of phenotype in plants | GREENVENUS, LLC (US) | 2023-01-17 | — | — | US | disclosed |
| US-11319380-B2 | MUC16 specific chimeric antigen receptors and uses thereof | PRECIGEN, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11154622-B2 | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies | PRECIGEN, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200283778-A1 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | PRECIGEN, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| CN-110139933-A | Frataxin expression construct | 英特瑞克斯顿股份有限公司 | 2019-08-16 | — | — | CN | disclosed |
| US-20190233834-A1 | CONTROL OF PHENOTYPE IN PLANTS | INTREXON CORPORATION (US) | 2019-08-01 | — | — | US | disclosed |
| US-20180360992-A1 | COMPOSITIONS AND METHODS FOR EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLYPEPTIDES FROM A SINGLE VECTOR FOR TREATMENT OF CARDIAC CONDITIONS AND OTHER PATHOLOGIES | PRECIGEN, INC. | 2018-12-20 | — | — | US | disclosed |
| WO-2018156818-A1 | NUCLEIC ACID CONSTRUCTS COMPRISING GENE EDITING MULTI-SITES AND USES THEREOF | IO BIOSCIENCES, INC. (US) | 2018-08-30 | — | — | WO | disclosed |
| EP-2167458-B1 | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2018-03-14 | — | — | EP | disclosed |
| US-9402919-B2 | Vectors conditionally expressing protein | INTREXON CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140308247-A1 | Vectors Conditionally Expressing Protein | INTREXON CORPORATION (US) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308247-A1 | Vectors Conditionally Expressing Protein | HAVCR2, MPEG1, TNFSF11 | ABCB1 2813/4885TAS1R3 4269/4885TAS1R1 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.